Immunological cell type characterization and Th1-Th17 cytokine production in a mouse model of Gaucher disease

Molecular Genetics and Metabolism

Volumn 106, Issue 3, 2012, Pages 310-322

  Pandey, Manoj Kumar ^a,b   Rani, Reena ^a,b   Zhang, Wujuan ^a,b   Setchell, Kenneth ^a,b   Grabowski, Gregory A ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Antigen presenting cell; Cytokine; Gaucher disease; Glucosylceramide; Lymphocyte; Stimulatory and co stimulatory molecules

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD69 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GLUCOSYLCERAMIDE; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 17F; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ARTICLE; BONE MARROW; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FLUORESCENCE ACTIVATED CELL SORTING; GAUCHER DISEASE; LIVER; LUNG; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TH1 CELL; TH17 CELL;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD28; ANTIGENS, CD3; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; GAUCHER DISEASE; MACROPHAGES; MICE; MICE, INBRED STRAINS; SPLEEN; TH1 CELLS; TH17 CELLS;

MUS;

EID: 84862582207     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.04.020     Document Type: Article

References (57)

1. Xu Y.H., Quinn B., Witte D., Grabowski G.A. Viable mouse models of acid β-glucosidase deficiency: the defect in Gaucher disease. Am. J. Pathol. 2003, 163:2093-2101.
2. Zimmer K.P., le Coutre P., Aerts H.M., Harzer K., Fukuda M., O'Brien J.S., Naim H.Y. Intracellular transport of acid β-glucosidase and lysosome-associated membrane proteins is affected in Gaucher's disease (G202R mutation). J. Pathol. 1999, 188:407-414.
3. Liou B., Kazimierczuk A., Zhang M., Scott C.R., Hegde R.S., Grabowski G.A. Analyses of variant acid β-glucosidases: effects of Gaucher disease mutations. J. Biol. Chem. 2006, 281:4242-4253.
4. Sawkar A.R., Schmitz M., Zimmer K.P., Reczek D., Edmunds T., Balch W.E., Kelly J.W. Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants. ACS Chem. Biol. 2006, 1:235-251.
5. Grabowski G.A. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008, 372:1263-1271.
6. Grabowski G.A., Petsko G.A., Kolodny E.H. Gaucher disease. The Online Metabolic and Molecular Bases of Inherited Disease 2010, 1-13. Mc Graw Hill, New York. D. Valle, A.L. Beaudet, B. Vogelstein, K.W. Kinzler, S.E. Antonarakis, A. Ballabio (Eds.).
7. Grabowski G.A. Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet. Test. 1997, 1:5-12.
8. Charrow J., Andersson H.C., Kaplan P., Kolodny E.H., Mistry P., Pastores G., Rosenbloom B.E., Scott C.R., Wappner R.S., Weinreb N.J., Zimran A. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch. Intern. Med. 2000, 160:2835-2843.
9. Cullen V., Sardi S.P., Ng J., Xu Y.H., Sun Y., Tomlinson J.J., Kolodziej P., Kahn I., Saftig P., Woulfe J., Rochet J.C., Glicksman M.A., Cheng S.H., Grabowski G.A., Shihabuddin L.S., Schlossmacher M.G. Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing. Ann. Neurol. 2011, 69:940-953.
10. Hughes D., Cappellini M.D., Berger M., Van Droogenbroeck J., de Fost M., Janic D., Marinakis T., Rosenbaum H., Villarubia J., Zhukovskaya E., Hollak C. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br. J. Haematol. 2007, 138:676-686.
11. Campeau P.M., Rafei M., Boivin M.N., Sun Y., Grabowski G.A., Galipeau J. Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome. Blood 2009, 114:3181-3190.
12. Basu S., Kaufman B., Roseman S. Enzymatic synthesis of ceramide-glucose and ceramide-lactose by glycosyltransferases from embryonic chicken brain. J. Biol. Chem. 1968, 243:5802-5804.
13. Huwiler A., Kolter T., Pfeilschifter J., Sandhoff K. Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim. Biophys. Acta 2000, 1485:63-99.
14. Tepper A.D., Diks S.H., van Blitterswijk W.J., Borst J. Glucosylceramide synthase does not attenuate the ceramide pool accumulating during apoptosis induced by CD95 or anti-cancer regimens. J. Biol. Chem. 2000, 275:34810-34817.
15. Liu Y.Y., Han T.Y., Giuliano A.E., Cabot M.C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 2001, 15:719-730.
16. Shen W., Stone K., Jales A., Leitenberg D., Ladisch S. Inhibition of TLR activation and up-regulation of IL-1R-associated kinase-M expression by exogenous gangliosides. J. Immunol. 2008, 180:4425-4432.
17. Kim T.J., Kang Y.J., Lim Y., Lee H.W., Bae K., Lee Y.S., Yoo J.M., Yoo H.S., Yun Y.P. Ceramide 1-phosphate induces neointimal formation via cell proliferation and cell cycle progression upstream of ERK1/2 in vascular smooth muscle cells. Exp. Cell Res. 2011, 317:2041-2051.
18. Popa I., Therville N., Carpentier S., Levade T., Cuvillier O., Portoukalian J. Production of multiple brain-like ganglioside species is dispensable for fas-induced apoptosis of lymphoid cells. PLoS One 2011, 6:e19974.
19. Chuang Y.H., Wang T.C., Jen H.Y., Yu A.L., Chiang B.L. α-galactosylceramide-induced airway eosinophilia is mediated through the activation of NKT cells. J. Immunol. 2011, 186:4687-4692.
20. Mather A.R., Siskind L.J. Glycosphingolipids and kidney disease. Adv. Exp. Med. Biol. 2011, 721:121-138.
21. Yamashita T. Glycosphingolipid modification: structural diversity, functional and mechanistic integration of diabetes. Diab. Metab. J. 2011, 35:309-316.
22. van Breemen M.J., de Fost M., Voerman J.S., Laman J.D., Boot R.G., Maas M., Hollak C.E., Aerts J.M., Rezaee F. Increased plasma macrophage inflammatory protein (MIP)-1α and MIP-1 β levels in type 1 Gaucher disease. Biochim. Biophys. Acta 2007, 1772:788-796.
23. Yoshino M., Watanabe Y., Tokunaga Y., Harada E., Fujii C., Numata S., Harada M., Tajima A., Ida H. Roles of specific cytokines in bone remodeling and hematopoiesis in Gaucher disease. Pediatr. Int. 2007, 49:959-965.
24. de Fost M., Out T.A., de Wilde F.A., Tjin E.P., Pals S.T., van Oers M.H., Boot R.G., Aerts J.F., Maas M., Vom Dahl S., Hollak C.E. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann. Hematol. 2008, 87:439-449.
25. Souza H.P., Frediani D., Cobra A.L., Moretti A.I., Jurado M.C., Fernandes T.R., Cardounel A.J., Zweier J.L., Tostes R.C. Angiotensin II modulates CD40 expression in vascular smooth muscle cells. Clin. Sci. (Lond) 2009, 116:423-431.
26. Godoy L.C., Moretti A.I., Jurado M.C., Oxer D., Janiszewski M., Ckless K., Velasco I.T., Laurindo F.R., Souza H.P. Loss of CD40 endogenous S-nitrosylation during inflammatory response in endotoxemic mice and patients with sepsis. Shock 2010, 33:626-633.
27. Marim F.M., Silveira T.N., Lima D.S., Zamboni D.S. A method for generation of bone marrow-derived macrophages from cryopreserved mouse bone marrow cells. PLoS One 2010, 5:e15263.
28. Zamboni D.S., Rabinovitch M. Nitric oxide partially controls Coxiella burnetii phase II infection in mouse primary macrophages. Infect. Immun. 2003, 71:1225-1233.
29. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., Muramatsu S., Steinman R.M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 1992, 176:1693-1702.
30. Iezzi G., Sonderegger I., Ampenberger F., Schmitz N., Marsland B.J., Kopf M. CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:876-881.
31. Witowski J., Pawlaczyk K., Breborowicz A., Scheuren A., Kuzlan-Pawlaczyk M., Wisniewska J., Polubinska A., Friess H., Gahl G.M., Frei U., Jorres A. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO α chemokine from mesothelial cells. J. Immunol. 2000, 165:5814-5821.
32. Forlow S.B., Schurr J.R., Kolls J.K., Bagby G.J., Schwarzenberger P.O., Ley K. Increased granulopoiesis through interleukin-17 and granulocyte colony-stimulating factor in leukocyte adhesion molecule-deficient mice. Blood 2001, 98:3309-3314.
33. Cua D.J., Tato C.M. Innate IL-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol. 2010, 10:479-489.
34. Momcilovic M., Miljkovic Z., Popadic D., Miljkovic D., Mostarica-Stojkovic M. Kinetics of IFN-γ and IL-17 expression and production in active experimental autoimmune encephalomyelitis in Dark Agouti rats. Neurosci. Lett. 2008, 447:148-152.
35. Li L., Huang L., Vergis A.L., Ye H., Bajwa A., Narayan V., Strieter R.M., Rosin D.L., Okusa M.D. IL-17 produced by neutrophils regulates IFN-γ-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J. Clin. Invest. 2010, 120:331-342.
36. Takeuchi O., Akira S. RIG-I-like antiviral protein in flies. Nat. Immunol. 2008, 9:1327-1328.
37. Matzinger P. Friendly and dangerous signals: is the tissue in control?. Nat. Immunol. 2007, 8:11-13.
38. Alisi A., Carsetti R., Nobili V. Pathogen- or damage-associated molecular patterns during nonalcoholic fatty liver disease development. Hepatology 2011, 54:1500-1502.
39. Pisetsky D.S., Gauley J., Ullal A.J. HMGB1 and microparticles as mediators of the immune response to cell death. Antioxid. Redox Signal. 2011, 15:2209-2219.
40. Ochiel D.O., Rossoll R.M., Schaefer T.M., Wira C.R. Effect of estradiol and pathogen associated molecular patterns (PAMP) on class II-mediated antigen presentation and immunomodulatory molecule expression in the mouse female reproductive tract. Immunology 2011, 135:51-62.
41. Durie F.H., Fava R.A., Foy T.M., Aruffo A., Ledbetter J.A., Noelle R.J. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993, 261:1328-1330.
42. Adawi A., Zhang Y., Baggs R., Finkelstein J., Phipps R.P. Disruption of the CD40-CD40 ligand system prevents an oxygen-induced respiratory distress syndrome. Am. J. Pathol. 1998, 152:651-657.
43. van Kooten C., Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 2000, 67:2-17.
44. Diaz-Montero C.M., El Naggar S., Al Khami A., El Naggar R., Montero A.J., Cole D.J., Salem M.L. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model. Cancer Immunol. Immunother. 2008, 57:563-572.
45. Henry C.J., Grayson J.M., Brzoza-Lewis K.L., Mitchell L.M., Westcott M.M., Cook A.S., Hiltbold E.M. The roles of IL-12 and IL-23 in CD8+ T cell-mediated immunity against Listeria monocytogenes: insights from a DC vaccination model. Cell. Immunol. 2010, 264:23-31.
46. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., Kleinschek M.A., Owyang A., Mattson J., Blumenschein W., Murphy E., Sathe M., Cua D.J., Kastelein R.A., Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 2006, 116:1310-1316.
47. Jiang X.F., Cui Z.M., Zhu L., Guo D.W., Sun W.Y., Lin L., Wang X.F., Tang Y.F., Liang J. CD40-CD40L costimulation blockade induced the tolerogenic dendritic cells in mouse cardiac transplant. Int. Surg. 2010, 95:135-141.
48. Nyakeriga A.M., Ying J., Shire N.J., Fichtenbaum C.J., Chougnet C.A. Highly active antiretroviral therapy in patients infected with human immunodeficiency virus increases CD40 ligand expression and IL-12 production in cells ex vivo. Viral Immunol. 2011, 24:281-289.
49. Baker R.L., Mallevaey T., Gapin L., Haskins K. T cells interact with T cells via CD40-CD154 to promote autoimmunity in type 1 diabetes. Eur. J. Immunol. 2012, 42:672-680.
50. Sakai H., Okafuji I., Nishikomori R., Abe J., Izawa K., Kambe N., Yasumi T., Nakahata T., Heike T. The CD40-CD40L axis and IFN-γ play critical roles in Langhans giant cell formation. Int. Immunol. 2012, 24:5-15.
51. Noelle R.J. CD40 and its ligand in host defense. Immunity 1996, 4:415-419.
52. Katzman S.D., Gallo E., Hoyer K.K., Abbas A.K. Differential requirements for Th1 and th17 responses to a systemic self-antigen. J. Immunol. 2011, 186:4668-4673.
53. Harrington L.E., Mangan P.R., Weaver C.T. Expanding the effector CD4 T-cell repertoire: the Th17 lineage. Curr. Opin. Immunol. 2006, 18:349-356.
54. Martinez G.J., Nurieva R.I., Yang X.O., Dong C. Regulation and function of proinflammatory TH17 cells. Ann. N. Y. Acad. Sci. 2008, 1143:188-211.
55. Zhu J., Yamane H., Paul W.E. Differentiation of effector CD4 T cell populations (*). Annu. Rev. Immunol. 2010, 28:445-489.
56. Hoeve M.A., Savage N.D., de Boer T., Langenberg D.M., de Waal Malefyt R., Ottenhoff T.H., Verreck F.A. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur. J. Immunol. 2006, 36:661-670.
57. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.